(Reuters) - Merck & Co Inc said on Monday it would buy $1 billion worth of equity stake in Seattle Genetics’s common stock.
The companies also said they would co-develop and sell Seattle Genetics's cancer therapy, ladiratuzumab vedotin. ( reut.rs/3bWTEvS)
Reporting by Trisha Roy in Bengaluru; Editing by Rashmi Aich
Our Standards: The Thomson Reuters Trust Principles.